Paper Details

  1. Home
  2. Paper Details

Sevelamer use and incidence of peritonitis in peritoneal dialysis.

Author: HausdorferJohann, KerschbaumJulia, KönigPaul, MayerGert, RudnickiMichael

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treatment with Sevelamer is not associated with a higher risk for peritonitis. The mean peritonitis incidence rate was to 0.50/patient year. An identified risk factor for peritonitis was time on PD. Neither Sevelamer use in general nor the mean daily intake was associated with the risk for peritonitis even after adjustment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Sevelamer, a non-calcium containing phosphate binder often used in end-stage renal disease, is frequently associated with gastrointestinal side effects. However, whether Sevelamer is also a risk factor for peritonitis in patients on peritoneal dialysis (PD) is unclear. METHODS: We perfo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00508-011-1551-1

データ提供：米国国立医学図書館（NLM）

Sevelamer and Peritonitis in Peritoneal Dialysis: A Desert of Uncertainty

Peritoneal dialysis, a life-sustaining treatment for kidney failure, is a journey through a desert of health challenges. This study explores the relationship between sevelamer, a medication used to control phosphate levels, and the risk of peritonitis, a potentially dangerous infection. Like a camel navigating a treacherous dune, researchers are seeking to understand the potential connection between these two factors, and how they may influence the well-being of patients undergoing peritoneal dialysis.

This study, like a well-placed oasis in the desert, provides reassurance that sevelamer doesn't seem to increase the risk of peritonitis.

Navigating the Desert of Dialysis

The study found that while time on peritoneal dialysis was associated with a higher risk of peritonitis, sevelamer itself didn't seem to play a role. This is encouraging news for patients undergoing this treatment, offering a sense of stability in the ever-changing landscape of dialysis.

Living with Peritoneal Dialysis

This research underscores the importance of meticulous care and attention to detail in managing peritoneal dialysis. It's a reminder that the desert of health requires constant vigilance and close collaboration between patients and their medical teams.

Dr. Camel's Conclusion

This study provides valuable insights into the complex interplay between medications and health outcomes. It's a reminder that the desert of medical research is full of surprises, and that continuous exploration is key to uncovering the secrets of health and disease.

Date :
  1. Date Completed 2011-09-26
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21442203

DOI: Digital Object Identifier

10.1007/s00508-011-1551-1

Related Literature

Article Analysis
・Side Effects of sevelamer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.